Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
In the proposed trial, patients will be administered ribociclib prior to surgical resection
of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized).
All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose
occurring at one of 3 intervals before brain tumor resection.
Phase:
Early Phase 1
Details
Lead Sponsor:
Nader Sanai St. Joseph's Hospital and Medical Center, Phoenix
Collaborators:
Barrow Neurological Institute Ivy Brain Tumor Center Novartis